Clinical Trial: Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda(R) as Adjuvant Monotherapy in Patients With Melanoma

U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07581509) titled 'Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda(R) as Adjuvant Monotherapy in Patients With Melanoma' on May 06.

Brief Summary: The purpose of the study is to evaluate the pharmacokinetic (PK) equivalence of Bmab1800 as compared with reference product Keytruda(R) in a randomized, double-blind, two-arm, parallel comparative, multi-center study in patients with resected melanoma (Stage IIB, or Stage IIC, or Stage III) as an adjuvant treatment. This study also compares the safety and immunogenicity of Bmab1800 and Keytruda.

Study Start Date: Aug. 01, 2026

Study Type: INTERVENTIONAL

Condition: Adult Patients Wit...